S9318

Sandoz 58-035

>98% (HPLC), powder, acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor

• Synonim(y): 3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenethyl]propanamide, SA 58-035
• Wzór empiryczny (zapis Hilla): C₃₀H₄₇NOSi
• Numer CAS: 78934-83-5
• Masa cząsteczkowa: 465.79
• UNSPSC Code: 41121801
• PubChem Substance ID: 24278227
• NACRES: NA.77
• MDL number: MFCD00161339
• Assay: >98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: Sandoz 58-035, >98% (HPLC), powder
• Quality Segment: 100
• assay: >98% (HPLC)
• form: powder
• color: white
• solubility: DMSO: 16 mg/mL, H₂O: insoluble
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: CCCCCCCCCC[Si](C)(C)CCC(=O)NC(Cc1ccc(C)cc1)c2ccccc2
• InChI: 1S/C30H47NOSi/c1-5-6-7-8-9-10-11-15-23-33(3,4)24-22-30(32)31-29(28-16-13-12-14-17-28)25-27-20-18-26(2)19-21-27/h12-14,16-21,29H,5-11,15,22-25H2,1-4H3,(H,31,32)
• InChI key: NBYATBIMYLFITE-UHFFFAOYSA-N
• Gene Information: human ... SOAT1(6646) ; rat ... Soat1(81782)

Opis

Application

Sandoz 58-035 was used to induce simultaneous activation of unfolded protein response (UPR) and pattern recognition receptors (PRRs) in mouse peritoneal macrophages.³

Biochem/physiol Actions

Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor.

Sandoz 58-035 inhibits the accumulation of cholesteryl esters and inhibits the esterification of cholesterol by 95% in arterial smooth muscle cells in culture.¹ It does not affect the triglyceride metabolism by the gut.²

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)